Replies to post #122220 on Biotech Values

[oc631]

It's hard to find any info on it since it's preclinical.

the pre-clinical development of BCX5191, a novel and proprietary

nucleoside analog targeting RNA polymerase for hepatitis C with a goal

for IND filing in 2012

http://sg.news.yahoo.com/bc-nc-biocryst-pharm-104532860.html

[flatlander_60048]

slide 20 from my earlier post indicates that the their nucleoside is capable of

"Rapid and efficient conversion to the triphosphate form and long triphosphate form half-life in human hepatocytes"

Does this make it any more viable?

regards
FL